H3 histamine receptor-mediated activation of protein kinase Cα inhibits the growth of cholangiocarcinoma in vitro and in vivo

Molecular Cancer Research

Volumn 7, Issue 10, 2009, Pages 1704-1713

  Francis, Heather ^a,b   Onori, Paolo ^e   Gaudio, Eugenio ^c   Franchitto, Antonio ^c   DeMorrow, Sharon ^a   Venter, Julie ^a   Kopriva, Shelley ^a   Carpino, Guido ^d   Mancinelli, Romina ^a,c,e   White, Mellanie ^a   Meng, Fanyin ^a,b   Vetuschi, Antonella ^e   Sferra, Roberta ^e   Alpini, Gianfranco ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b Division of Research and Education   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ROME FORO ITALICO   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYLHISTAMINE; CASPASE 3; CYCLIC AMP; CYCLINE; HISTAMINE H3 RECEPTOR; INOSITOL 1,4,5 TRISPHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C ALPHA; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVATION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HISTAMINE AGONISTS; HISTIDINE; HUMANS; MALE; METHYLHISTAMINES; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN KINASE C-ALPHA; RECEPTORS, HISTAMINE H3; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS; MUS MUSCULUS;

EID: 72449187627     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-09-0261     Document Type: Article

References (46)

1. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemo-prevention and therapy. Hepatology 2005;41:5-15. (Pubitemid 40066375)
2. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008;12: 131-50, ix.
3. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008;10:77-82. (Pubitemid 351934989)
4. Nguyen T, Shapiro DA, George SR, et al. Discovery of a novel member of the histamine receptor family. Mol Pharmacol 2001;59:427-433 (Pubitemid 32179919)
5. Repka-Ramirez MS. New concepts of histamine receptors and actions. Curr Allergy Asthma Rep 2003;3:227-231 (Pubitemid 38899097)
6. Francis H, Franchitto A, Ueno Y, et al. H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ ERK1/2/ELK-1 pathway. Lab Invest 2007;87:473-487 (Pubitemid 46633123)
7. Francis H, Glaser S, DeMorrowS, et al. Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/ CAMK I/CREB pathway. Am J Physiol Cell Physiol 2008;295:C499-513.
8. Hill SJ, Ganellin CR, Timmerman H, et al. International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 1997;49:253-278
9. Liu C, Ma X, Jiang X, et al. Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol 2001;59:420-426 (Pubitemid 32179918)
10. Lovenberg TW, Roland BL, Wilson SJ, et al. Cloning and functional expression of the human histamine H3 receptor. Mol Pharmacol 1999;55:1101-1107 (Pubitemid 29252378)
11. Endou M, Poli E, Levi R. Histamine H3-receptor signaling in the heart: possible involvement of Gi/Go proteins and N-type Ca2+ channels. J Pharmacol Exp Ther 1994;269:221-229 (Pubitemid 24143258)
12. Medina V, Croci M, Crescenti E, et al. The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther 2008;7:28-35.
13. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998;332:281-292
14. El-Rayes BF, Ali S, Philip PA, Sarkar FH. Protein kinase C: a target for therapy in pancreatic cancer. Pancreas 2008;36:346-352 (Pubitemid 351591576)
15. Wang CY, Lin YW, Yang JL. Activation of protein kinase Cá signaling prevents cytotoxicity and mutagenicity following lead acetate in CL3 human lung cancer cells. Toxicology 2008;250:55-61.
16. Takai Y, Kishimoto A, Iwasa Y, Kawahara Y, Mori T, Nishizuka Y. Calcium-dependent activation of a multifunctional protein kinase by membrane phospholipids. J Biol Chem 1979;254:3692-3695
17. Kikkawa U, Takai Y, Tanaka Y, Miyake R, Nishizuka Y. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem 1983; 258:11442-11445
18. Lerner M, Corcoran M, Cepeda D, et al. The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD. Mol Biol Cell 2007;18:1670-1682 (Pubitemid 46717549)
19. Levi R, Seyedi N, Schaefer U, et al. Histamine H3-receptor signaling in cardiac sympathetic nerves: identification of a novel MAPK-PLA2-COX-PGE2-3R pathway. Biochem Pharmacol 2007;73:1146-1156
20. Boer K, Helinger E, Helinger A, et al. Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine. Eur J Cell Biol 2008;87:227-236
21. Khan UW, Rai U. Differential effects of histamine on Leydig cell and testicular macrophage activities in wall lizards: precise role of H1/H2 receptor subtypes. J Endocrinol 2007;194:441-448 (Pubitemid 47249680)
22. Alpini G, Kanno N, Phinizy JL, et al. Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol 2004;286:G973-82.
23. Glaser S, Benedetti A, Marucci L, et al. Gastrin inhibits cholangiocyte growth in bile duct-ligated rats by interaction with cholecystokinin-B/gastrin receptors via D-myo-inositol 1,4,5-triphosphate-, Ca2+-, and protein kinase Cá-dependent mechanisms. Hepatology 2000;32:17-25.
24. Kanno N, Glaser S, Chowdhury U, et al. Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of Ca2+-dependent protein kinase C-á. J Hepatol 2001;284-291 (Pubitemid 32176451)
25. Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev 2009;35:1-8.
26. Wen-Sheng W, Jun-Ming H. Activation of protein kinase C á is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2. J Biomed Sci 2005;12:289-296 (Pubitemid 40897636)
27. Fava G, Marucci L, Glaser S, et al. ã-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 2005;65: 11437-11446 (Pubitemid 41821701)
28. Gaudio E, Barbaro B, Alvaro D, et al. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006;130:1270-1282
29. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006;94:1154-1163
30. Hawinkels LJ, Zuidwijk K, Verspaget HW, et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 2008;44:1904-1913
31. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag 2006;2:213-219
32. Sen T, Moulik S, Dutta A, et al. Multifunctional effect of epigallocatechin-3- gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci 2009;84:194-204.
33. Wang W Jia, WD Xu GL, et al. Antitumoral activity of rapamycin mediated through inhibition of HIF-1á and VEGF in hepatocellular carcinoma. Dig Dis Sci 2009;54:2128-2136
34. Knuth A, Gabbert H, Dippold W, et al. Biliary adenocarcinoma. Characterisation of three newhuman tumor cell lines. J Hepatol 1985;1:579-596 (Pubitemid 15015131)
35. Kusaka Y, Muraoka A, Tokiwa T, Sato J. Establishment and characterization of a human cholangiocellular carcinoma cell line. Hum Cell 1988;1:92-94
36. Shimizu Y, Demetris AJ, Gollin SM, et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 1992;52:252-260
37. Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes Cancer 1990;2:300-310
38. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol 1989;25:503-510 (Pubitemid 19177403)
39. Grubman SA, Perrone RD, Lee DW, et al. Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines. Am J Physiol Gastrointest Liver Physiol 1994;266:G1060-70.
40. DeMorrowS, Glaser S, Francis H, et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 2007;282:13098-13113 (Pubitemid 47100640)
41. Alpini G, Invernizzi P, Gaudio E, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 2008:9184-9193
42. Shayo C, Fernandez N, Legnazzi BL, et al. Histamine H2 receptor desensitization: involvement of a select array of G protein-coupled receptor kinases. Mol Pharmacol 2001;60:1049-1056 (Pubitemid 33027440)
43. Baumer W, Wendorff S, Gutzmer R, et al. Histamine H4 receptors modulate dendritic cell migration through skin-immunomodulatory role of histamine. Allergy 2008;63:1387-1394
44. Kato A, Gores GJ, LaRusso NF. Secretin stimulates exocytosis in isolated bile duct epithelial cells by a cyclic AMP-mediated mechanism. J Biol Chem 1992;267:15523-15529
45. Kanno N, LeSage G, Phinizy JL, Glaser S, Francis H, Alpini G. Stimulation of á2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology 2002;35:1329-1340 (Pubitemid 34966887)
46. Girard P, Pansart Y, Coppe MC, Verniers D, Gillardin JM. Role of the histamine system in nefopam-induced antinociception in mice. Eur J Pharmacol 2004;503:63-69 (Pubitemid 39445942)